VIVOTIF DIN 00885975
Status: Marketed
Holder: BAVARIAN NORDIC AS
Molecule: SALMONELLA TYPHI TY21A LIVE ATTENUATED
Available to quote
Health Canada record
| Active ingredient(s) | SALMONELLA TYPHI TY21A LIVE ATTENUATED 10000000000 CFU |
|---|---|
| Dosage form | Capsule (Enteric-Coated) |
| Route | Oral |
| Schedule | SCHEDULE D |
| Class | Human |
| ATC | J07AP01 TYPHOID, ORAL, LIVE ATTENUATED |
| Original market date | 01-Jan-1993 |
| Current status date | 14-Nov-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Bavarian Nordic GmbH — licence , not currently licensed, last inspection rating I (2026-06-10).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 32407 | 2023-12-27 | New Drug Submission (NDS) | Administrative - Change in Product Ownership |
| 24644 | 2020-11-13 | New Drug Submission (NDS) | CHANGE IN PRODUCT OWNERHSIP |
| 23579 | 2020-05-07 | New Drug Submission (NDS) | MANUFACTURER NAME CHANGE |
| 16567 | 2015-01-23 | New Drug Submission (NDS) | MANUFACTURER NAME CHANGE |
| 11150 | 2010-03-16 | New Drug Submission (NDS) | Manufacturer name change |
| 846 | 2002-05-02 | New Drug Submission (NDS) | MANUFACTURER AND PRODUCT NAME CHANGE |
| 5598 | 1994-08-25 | Supplement to a New Drug Submission (SNDS) | REVISED PRODUCT MONOGRAPH |